Fireside chat: AAV at scale without compromise: How the field is fixing manufacturing bottlenecks and toxicity risk without slowing clinical momentum

AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the efficiency and scalability gap.

Toxicity is the gating factor not delivery: How the field’s understanding of AAV-associated toxicities (including hepatotoxicity, neurotoxicity, TMA and cardiotoxicity) has evolved and which mitigation strategies are showing real-world impact today.

Designing safety in, not reacting later: How advances in vector engineering, capsid design, dosing strategies and patient selection are reducing risk earlier in development shifting toxicity management upstream.

Monitoring, intervention and control: The latest approaches to AAV monitoring, immune response management and clinical intervention protocols and how these are being operationalised in trials.

Next-generation vectors and rare disease potential: How emerging AAV variants and next-gen vector platforms aim to expand the therapeutic window, improve tissue targeting and further mitigate toxicity particularly in rare disease indications.